Global assessment of the COPD patient: Time to look beyond FEV1?

Respiratory Medicine

Volumn 103, Issue 5, 2009, Pages 650-660

  Papaioannou, Andriana I ^a   Loukides, Stelios ^b   Gourgoulianis, Konstantinos I ^a   Kostikas, Konstantinos ^a  

^a UNIVERSITY OF THESSALY   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

BODE index; Chronic obstructive pulmonary disease; Dyspnea; FEV1; Phenotypes

Indexed keywords

BIOLOGICAL MARKER;

AIRFLOW; BODY COMPOSITION; BODY MASS; CHRONIC BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; COMORBIDITY; DISEASE EXACERBATION; DYSPNEA; EMPHYSEMA; EXERCISE; GENOMICS; HUMAN; LUNG EXAMINATION; LUNG FUNCTION; PHENOTYPE; PNEUMONIA; PRIORITY JOURNAL; QUALITY OF LIFE; RADIODIAGNOSIS; REVIEW; SEX DIFFERENCE; SMOKING HABIT; SPIROMETRY; THORAX RADIOGRAPHY;

BIOLOGICAL MARKERS; BODY MASS INDEX; COMORBIDITY; DISEASE PROGRESSION; DYSPNEA; EXERCISE TOLERANCE; FORCED EXPIRATORY VOLUME; HUMANS; PHENOTYPE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; SEVERITY OF ILLNESS INDEX;

EID: 62949198632     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2009.01.001     Document Type: Review

References (120)

1. Celli B.R., and MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 23 6 (2004 Jun) 932-946
2. Rabe K.F., Hurd S., Anzueto A., Barnes P.J., Buist S.A., Calverley P., et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176 6 (2007 Sep 15) 532-555
3. Thomason M.J., and Strachan D.P. Which spirometric indices best predict subsequent death from chronic obstructive pulmonary disease?. Thorax 55 9 (2000 Sep) 785-788
4. Donaldson G.C., Seemungal T.A., Patel I.S., Bhowmik A., Wilkinson T.M., Hurst J.R., et al. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 128 4 (2005 Oct) 1995-2004
5. Agusti A.G. Systemic effects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2 4 (2005) 367-370 [discussion: 71-72]
6. Mahler D.A., and Criner G.J. Assessment tools for chronic obstructive pulmonary disease: do newer metrics allow for disease modification?. Proc Am Thorac Soc 4 7 (2007 Oct) 507-511
7. Celli B.R., and Roger S. Mitchell lecture. Chronic obstructive pulmonary disease phenotypes and their clinical relevance. Proc Am Thorac Soc 3 6 (2006 Aug) 461-465
8. Pierce R. Spirometry: an essential clinical measurement. Aust Fam Physician 34 7 (2005 Jul) 535-539
9. Jones P.W., and Agusti A.G. Outcomes and markers in the assessment of chronic obstructive pulmonary disease. Eur Respir J 27 4 (2006 Apr) 822-832
10. O'Donnell D.E. Assessment of bronchodilator efficacy in symptomatic COPD: is spirometry useful?. Chest 117 2 Suppl. (2000 Feb) 42S-47S
11. Lacasse Y., Goldstein R., Lasserson T.J., and Martin S. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 4 (2006) CD003793
12. Enright P.L., Johnson L.R., Connett J.E., Voelker H., and Buist A.S. Spirometry in the Lung Health Study. 1. Methods and quality control. Am Rev Respir Dis 143 6 (1991 Jun) 1215-1223
13. Calverley P.M., Burge P.S., Spencer S., Anderson J.A., and Jones P.W. Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 58 8 (2003 Aug) 659-664
14. Swanney M.P., Jensen R.L., Crichton D.A., Beckert L.E., Cardno L.A., and Crapo R.O. FEV(6) is an acceptable surrogate for FVC in the spirometric diagnosis of airway obstruction and restriction. Am J Respir Crit Care Med 162 3 Pt 1 (2000 Sep) 917-919
15. Enright R.L., Connett J.E., and Bailey W.C. The FEV1/FEV6 predicts lung function decline in adult smokers. Respir Med 96 6 (2002 Jun) 444-449
16. Vandevoorde J., and Swanney M. Is forced expiratory volume in six seconds a valid alternative to forced vital capacity?. Eur Respir J 28 6 (2006 Dec) 1288-1289 [author reply 9-90]
17. Mannino D.M., Sonia Buist A., and Vollmer W.M. Chronic obstructive pulmonary disease in the older adult: what defines abnormal lung function?. Thorax 62 3 (2007 Mar) 237-241
18. O'Donnell D.E., Revill S.M., and Webb K.A. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164 5 (2001 Sep 1) 770-777
19. Casanova C., Cote C., de Torres J.P., Aguirre-Jaime A., Marin J.M., Pinto-Plata V., et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 6 (2005 Mar 15) 591-597
20. Sherrill D.L., Enright P.L., Kaltenborn W.T., and Lebowitz M.D. Predictors of longitudinal change in diffusing capacity over 8 years. Am J Respir Crit Care Med 160 6 (1999 Dec) 1883-1887
21. Cotton D.J., Soparkar G.R., and Grahan B.L. Diffusing capacity in the clinical assessment of chronic airflow limitation. Med Clin North Am 80 3 (1996 May) 549-564
22. Gould G.A., Redpath A.T., Ryan M., Warren P.M., Best J.J., Flenley D.C., et al. Lung CT density correlates with measurements of airflow limitation and the diffusing capacity. Eur Respir J 4 2 (1991 Feb) 141-146
23. Macintyre N., Crapo R.O., Viegi G., Johnson D.C., van der Grinten C.P., Brusasco V., et al. Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J 26 4 (2005 Oct) 720-735
24. American Thoracic Society. Single-breath carbon monoxide diffusing capacity (transfer factor). Recommendations for a standard technique - 1995 update. Am J Respir Crit Care Med 152 6 Pt 1 (1995 Dec) 2185-2198
25. Sin D.D., and Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 107 11 (2003 Mar 25) 1514-1519
26. Mannino D.M., Aguayo S.M., Petty T.L., and Redd S.C. Low lung function and incident lung cancer in the United States: data from the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 163 12 (2003 Jun 23) 1475-1480
27. Makita H., Nasuhara Y., Nagai K., Ito Y., Hasegawa M., Betsuyaku T., et al. Characterisation of phenotypes based on severity of emphysema in chronic obstructive pulmonary disease. Thorax 62 11 (2007 Nov) 932-937
28. Friedman P.J. Imaging studies in emphysema. Proc Am Thorac Soc 5 4 (2008 May 1) 494-500
29. Ambrosino N., and Serradori M. Determining the cause of dyspnoea: linguistic and biological descriptors. Chron Respir Dis 3 3 (2006) 117-122
30. Hajiro T., Nishimura K., Tsukino M., Ikeda A., Koyama H., and Izumi T. Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 158 4 (1998 Oct) 1185-1189
31. Nishimura K., Izumi T., Tsukino M., and Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in patients with COPD. Chest 121 5 (2002 May) 1434-1440
32. Hajiro T., Nishimura K., Tsukino M., Ikeda A., Oga T., and Izumi T. A comparison of the level of dyspnea vs disease severity in indicating the health-related quality of life of patients with COPD. Chest 116 6 (1999 Dec) 1632-1637
33. Bestall J.C., Paul E.A., Garrod R., Garnham R., Jones P.W., and Wedzicha J.A. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 54 7 (1999 Jul) 581-586
34. Wedzicha J.A., Bestall J.C., Garrod R., Garnham R., Paul E.A., and Jones P.W. Randomized controlled trial of pulmonary rehabilitation in severe chronic obstructive pulmonary disease patients, stratified with the MRC dyspnoea scale. Eur Respir J 12 2 (1998 Aug) 363-369
35. Mahler D.A., and Wells C.K. Evaluation of clinical methods for rating dyspnea. Chest 93 3 (1988 Mar) 580-586
36. Borg G.A. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 14 5 (1982) 377-381
37. Jones P.W., Quirk F.H., and Baveystock C.M. The St George's respiratory questionnaire. Respir Med 85 Suppl. B (1991 Sep) 25-31 [discussion: 3-7]
38. Agusti A.G., Noguera A., Sauleda J., Sala E., Pons J., and Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 21 2 (2003 Feb) 347-360
39. Landbo C., Prescott E., Lange P., Vestbo J., and Almdal T.P. Prognostic value of nutritional status in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160 6 (1999 Dec) 1856-1861
40. Celli B.R., Cote C.G., Marin J.M., Casanova C., Montes de Oca M., Mendez R.A., et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 350 10 (2004 Mar 4) 1005-1012
41. Prescott E., Almdal T., Mikkelsen K.L., Tofteng C.L., Vestbo J., and Lange P. Prognostic value of weight change in chronic obstructive pulmonary disease: results from the Copenhagen City Heart Study. Eur Respir J 20 3 (2002 Sep) 539-544
42. Vestbo J., Prescott E., Almdal T., Dahl M., Nordestgaard B.G., Andersen T., et al. Body mass, fat-free body mass, and prognosis in patients with chronic obstructive pulmonary disease from a random population sample: findings from the Copenhagen City Heart Study. Am J Respir Crit Care Med 173 1 (2006 Jan 1) 79-83
43. Erselcan T., Candan F., Saruhan S., and Ayca T. Comparison of body composition analysis methods in clinical routine. Ann Nutr Metab 44 5-6 (2000) 243-248
44. Schols A.M., Broekhuizen R., Weling-Scheepers C.A., and Wouters E.F. Body composition and mortality in chronic obstructive pulmonary disease. Am J Clin Nutr 82 1 (2005 Jul) 53-59
45. Hopkinson N.S., Tennant R.C., Dayer M.J., Swallow E.B., Hansel T.T., Moxham J., et al. A prospective study of decline in fat free mass and skeletal muscle strength in chronic obstructive pulmonary disease. Respir Res 8 (2007) 25
46. Ischaki E., Papatheodorou G., Gaki E., Papa I., Koulouris N., and Loukides S. Body mass and fat-free mass indices in COPD: relation with variables expressing disease severity. Chest 132 1 (2007 Jul) 164-169
47. Swallow E.B., Reyes D., Hopkinson N.S., Man W.D., Porcher R., Cetti E.J., et al. Quadriceps strength predicts mortality in patients with moderate to severe chronic obstructive pulmonary disease. Thorax 62 2 (2007 Feb) 115-120
48. Schols A. Nutritional modulation as part of the integrated management of chronic obstructive pulmonary disease. Proc Nutr Soc 62 4 (2003 Nov) 783-791
49. Pitta F., Troosters T., Spruit M.A., Probst V.S., Decramer M., and Gosselink R. Characteristics of physical activities in daily life in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 171 9 (2005 May 1) 972-977
50. Couillard A., and Prefaut C. From muscle disuse to myopathy in COPD: potential contribution of oxidative stress. Eur Respir J 26 4 (2005 Oct) 703-719
51. Palange P., Ward S.A., Carlsen K.H., Casaburi R., Gallagher C.G., Gosselink R., et al. Recommendations on the use of exercise testing in clinical practice. Eur Respir J 29 1 (2007 Jan) 185-209
52. Gross N.J. Extrapulmonary effects of chronic obstructive pulmonary disease. Curr Opin Pulm Med 7 2 (2001 Mar) 84-92
53. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166 1 (2002 Jul 1) 111-117
54. Enright P.L. The six-minute walk test. Respir Care 48 8 (2003 Aug) 783-785
55. Pinto-Plata V.M., Cote C., Cabral H., Taylor J., and Celli B.R. The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J 23 1 (2004 Jan) 28-33
56. Casanova C., Cote C.G., Marin J.M., de Torres J.P., Aguirre-Jaime A., Mendez R., et al. The 6-min walking distance: long-term follow up in patients with COPD. Eur Respir J 29 3 (2007 Mar) 535-540
57. Foley R.J., and ZuWallack R. The impact of nutritional depletion in chronic obstructive pulmonary disease. J Cardiopulm Rehabil 21 5 (2001 Sep-Oct) 288-295
58. Ware Jr. J.E., and Sherbourne C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care 30 6 (1992 Jun) 473-483
59. Gross N.J. Chronic obstructive pulmonary disease outcome measurements: what's important? What's useful?. Proc Am Thorac Soc 2 4 (2005) 267-271 [discussion: 90-91]
60. Jones P.W. Health status measurement in chronic obstructive pulmonary disease. Thorax 56 11 (2001 Nov) 880-887
61. Shoup R., Dalsky G., Warner S., Davies M., Connors M., Khan M., et al. Body composition and health-related quality of life in patients with obstructive airways disease. Eur Respir J 10 7 (1997 Jul) 1576-1580
62. Stahl E., Lindberg A., Jansson S.A., Ronmark E., Svensson K., Andersson F., et al. Health-related quality of life is related to COPD disease severity. Health Qual Life Outcomes 3 (2005) 56
63. Seemungal T.A., Donaldson G.C., Paul E.A., Bestall J.C., Jeffries D.J., and Wedzicha J.A. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 157 5 Pt 1 (1998 May) 1418-1422
64. Calverley P.M., Anderson J.A., Celli B., Ferguson G.T., Jenkins C., Jones P.W., et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356 8 (2007 Feb 22) 775-789
65. Smith A.D., Cowan J.O., Brassett K.P., Herbison G.P., and Taylor D.R. Use of exhaled nitric oxide measurements to guide treatment in chronic asthma. N Engl J Med 352 21 (2005 May 26) 2163-2173
66. Kostikas K., Koutsokera A., Papiris S., Gourgoulianis K.I., and Loukides S. Exhaled breath condensate in patients with asthma: implications for application in clinical practice. Clin Exp Allergy 38 4 (2008 Apr) 557-565
67. Sin D.D., and Man S.F. Skeletal muscle weakness, reduced exercise tolerance, and COPD: is systemic inflammation the missing link?. Thorax 61 1 (2006 Jan) 1-3
68. Dahl M., Vestbo J., Lange P., Bojesen S.E., Tybjaerg-Hansen A., and Nordestgaard B.G. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 175 3 (2007 Feb 1) 250-255
69. Hurst J.R., Perera W.R., Wilkinson T.M., Donaldson G.C., and Wedzicha J.A. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 173 1 (2006 Jan 1) 71-78
70. Broekhuizen R., Wouters E.F., Creutzberg E.C., and Schols A.M. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 61 1 (2006 Jan) 17-22
71. de Torres J.P., Pinto-Plata V., Casanova C., Mullerova H., Cordoba-Lanus E., Muros de Fuentes M., et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 133 6 (2008 Jun) 1336-1343
72. Fabbri L.M., and Rabe K.F. From COPD to chronic systemic inflammatory syndrome?. Lancet 370 9589 (2007 Sep 1) 797-799
73. Vestbo J., Anderson W., Coxson H.O., Crim C., Dawber F., Edwards L., et al. Evaluation of COPD longitudinally to identify predictive surrogate end-points (ECLIPSE). Eur Respir J 31 4 (2008 Apr) 869-873
74. Rennard S.I. Clinical approach to patients with chronic obstructive pulmonary disease and cardiovascular disease. Proc Am Thorac Soc 2 1 (2005) 94-100
75. Mapel D.W., Picchi M.A., Hurley J.S., Frost F.J., Petersen H.V., Mapel V.M., et al. Utilization in COPD: patient characteristics and diagnostic evaluation. Chest 117 5 Suppl. 2 (2000 May) 346S-353S
76. Mannino D.M., Watt G., Hole D., Gillis C., Hart C., McConnachie A., et al. The natural history of chronic obstructive pulmonary disease. Eur Respir J 27 3 (2006 Mar) 627-643
77. Gan W.Q., Man S.F., Senthilselvan A., and Sin D.D. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax 59 7 (2004 Jul) 574-580
78. Sidney S., Sorel M., Quesenberry Jr. C.P., DeLuise C., Lanes S., and Eisner M.D. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 128 4 (2005 Oct) 2068-2075
79. Falk J.A., Kadiev S., Criner G.J., Scharf S.M., Minai O.A., and Diaz P. Cardiac disease in chronic obstructive pulmonary disease. Proc Am Thorac Soc 5 4 (2008 May 1) 543-548
80. Bolton C.E., Ionescu A.A., Shiels K.M., Pettit R.J., Edwards P.H., Stone M.D., et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 170 12 (2004 Dec 15) 1286-1293
81. Shepherd A.J., Cass A.R., Carlson C.A., and Ray L. Development and internal validation of the male osteoporosis risk estimation score. Ann Fam Med 5 6 (2007 Nov-Dec) 540-546
82. Sin D.D., Anthonisen N.R., Soriano J.B., and Agusti A.G. Mortality in COPD: role of comorbidities. Eur Respir J 28 6 (2006 Dec) 1245-1257
83. van Manen J.G., Bindels P.J., Dekker F.W., IJzermans C.J., van der Zee J.S., and Schade E. Risk of depression in patients with chronic obstructive pulmonary disease and its determinants. Thorax 57 5 (2002 May) 412-416
84. Norwood R. Prevalence and impact of depression in chronic obstructive pulmonary disease patients. Curr Opin Pulm Med 12 2 (2006 Mar) 113-117
85. Quint J.K., Baghai-Ravary R., Donaldson G.C., and Wedzicha J.A. Relationship between depression and exacerbations in COPD. Eur Respir J 32 1 (2008 Jul) 53-60
86. Dowson C.A., Town G.I., Frampton C., and Mulder R.T. Psychopathology and illness beliefs influence COPD self-management. J Psychosom Res 56 3 (2004 Mar) 333-340
87. Xu W., Collet J.P., Shapiro S., Lin Y., Yang T., Platt R.W., et al. Independent effect of depression and anxiety on chronic obstructive pulmonary disease exacerbations and hospitalizations. Am J Respir Crit Care Med 178 9 (2008 Nov 1) 913-920
88. Maurer J., Rebbapragada V., Borson S., Goldstein R., Kunik M.E., Yohannes A.M., et al. Anxiety and depression in COPD: current understanding, unanswered questions, and research needs. Chest 134 4 Suppl. (2008 Oct) 43S-56S
89. Kempainen R.R., Savik K., Whelan T.P., Dunitz J.M., Herrington C.S., and Billings J.L. High prevalence of proximal and distal gastroesophageal reflux disease in advanced COPD. Chest 131 6 (2007 Jun) 1666-1671
90. Terada K., Muro S., Sato S., Ohara T., Haruna A., Marumo S., et al. Impact of gastro-oesophageal reflux disease symptoms on COPD exacerbation. Thorax 63 11 (2008 Nov) 951-955
91. Cote C., Zilberberg M.D., Mody S.H., Dordelly L.J., and Celli B. Haemoglobin level and its clinical impact in a cohort of patients with COPD. Eur Respir J 29 5 (2007 May) 923-929
92. Chambellan A., Chailleux E., and Similowski T. Prognostic value of the hematocrit in patients with severe COPD receiving long-term oxygen therapy. Chest 128 3 (2005 Sep) 1201-1208
93. Wedzicha J.A., and Seemungal T.A. COPD exacerbations: defining their cause and prevention. Lancet 370 9589 (2007 Sep 1) 786-796
94. Boyd C.M., Darer J., Boult C., Fried L.P., Boult L., and Wu A.W. Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 294 6 (2005 Aug 10) 716-724
95. Mannino D.M., Homa D.M., Akinbami L.J., Ford E.S., and Redd S.C. Chronic obstructive pulmonary disease surveillance - United States, 1971-2000. Respir Care 47 10 (2002 Oct) 1184-1199
96. de Torres J.P., Casanova C., Hernandez C., Abreu J., Aguirre-Jaime A., and Celli B.R. Gender and COPD in patients attending a pulmonary clinic. Chest 128 4 (2005 Oct) 2012-2016
97. Martinez F.J., Curtis J.L., Sciurba F., Mumford J., Giardino N.D., Weinmann G., et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med 176 3 (2007 Aug 1) 243-252
98. Machado M.C., Krishnan J.A., Buist S.A., Bilderback A.L., Fazolo G.P., Santarosa M.G., et al. Sex differences in survival of oxygen-dependent patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174 5 (2006 Sep 1) 524-529
99. Sin D.D., Wu L., Anderson J.A., Anthonisen N.R., Buist A.S., Burge P.S., et al. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 60 12 (2005 Dec) 992-997
100. Foy C.G., Rejeski W.J., Berry M.J., Zaccaro D., and Woodard C.M. Gender moderates the effects of exercise therapy on health-related quality of life among COPD patients. Chest 119 1 (2001 Jan) 70-76
101. Anthonisen N.R., Connett J.E., Kiley J.P., Altose M.D., Bailey W.C., Buist A.S., et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 272 19 (1994 Nov 16) 1497-1505
102. Anthonisen N.R., Skeans M.A., Wise R.A., Manfreda J., Kanner R.E., and Connett J.E. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 142 4 (2005 Feb 15) 233-239
103. de Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C., Muros de Fuentes M., Montejo de Garcini A., Aguirre-Jaime A., et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 27 5 (2006 May) 902-907
104. Godtfredsen N.S., Vestbo J., Osler M., and Prescott E. Risk of hospital admission for COPD following smoking cessation and reduction: a Danish population study. Thorax 57 11 (2002 Nov) 967-972
105. Barnes N.C., Qiu Y.S., Pavord I.D., Parker D., Davis P.A., Zhu J., et al. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173 7 (2006 Apr 1) 736-743
106. Anzueto A., Sethi S., and Martinez F.J. Exacerbations of chronic obstructive pulmonary disease. Proc Am Thorac Soc 4 7 (2007 Oct 1) 554-564
107. Almagro P., Calbo E., Ochoa de Echaguen A., Barreiro B., Quintana S., Heredia J.L., et al. Mortality after hospitalization for COPD. Chest 121 5 (2002 May) 1441-1448
108. Miravitlles M., Guerrero T., Mayordomo C., Sanchez-Agudo L., Nicolau F., and Segu J.L. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration 67 5 (2000) 495-501
109. Patel I.S., Seemungal T.A., Wilks M., Lloyd-Owen S.J., Donaldson G.C., and Wedzicha J.A. Relationship between bacterial colonisation and the frequency, character, and severity of COPD exacerbations. Thorax 57 9 (2002 Sep) 759-764
110. Aaron S.D., Vandemheen K.L., Clinch J.J., Ahuja J., Brison R.J., Dickinson G., et al. Measurement of short-term changes in dyspnea and disease-specific quality of life following an acute COPD exacerbation. Chest 121 3 (2002 Mar) 688-696
111. Donaldson G.C., Seemungal T.A., Bhowmik A., and Wedzicha J.A. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax 57 10 (2002 Oct) 847-852
112. Soler-Cataluna J.J., Martinez-Garcia M.A., Roman Sanchez P., Salcedo E., Navarro M., and Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 60 11 (2005 Nov) 925-931
113. Rennard S.I. Looking at the patient-approaching the problem of COPD. N Engl J Med 350 10 (2004 Mar 4) 965-966
114. Wouters E.F. Approaches to improving health status in chronic obstructive pulmonary disease: one or several?. Proc Am Thorac Soc 3 3 (2006 May) 262-269
115. Boschetto P., Quintavalle S., Zeni E., Leprotti S., Potena A., Ballerin L., et al. Association between markers of emphysema and more severe chronic obstructive pulmonary disease. Thorax 61 12 (2006 Dec) 1037-1042
116. DeMeo D.L., and Silverman E.K. Genetics of chronic obstructive pulmonary disease. Semin Respir Crit Care Med 24 2 (2003 Apr) 151-160
117. Caramori G., and Adcock I. Gene-environment interactions in the development of chronic obstructive pulmonary disease. Curr Opin Allergy Clin Immunol 6 5 (2006 Oct) 323-328
118. Ong K.C., Earnest A., and Lu S.J. A multidimensional grading system (BODE index) as predictor of hospitalization for COPD. Chest 128 6 (2005 Dec) 3810-3816
119. Cote C.G., Dordelly L.J., and Celli B.R. Impact of COPD exacerbations on patient-centered outcomes. Chest 131 3 (2007 Mar) 696-704
120. Martinez F.J., Han M.K., Andrei A.C., Wise R., Murray S., Curtis J.L., et al. Longitudinal change in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med (2008 Jun 5)